HLS Therapeutics Inc. (TSE:HLS - Free Report) - Research analysts at Stifel Canada dropped their FY2024 earnings per share (EPS) estimates for shares of HLS Therapeutics in a research note issued to investors on Tuesday, November 12th. Stifel Canada analyst J. Keywood now expects that the company will post earnings of ($0.88) per share for the year, down from their prior forecast of ($0.86). The consensus estimate for HLS Therapeutics' current full-year earnings is ($0.12) per share. Stifel Canada also issued estimates for HLS Therapeutics' Q4 2024 earnings at ($0.15) EPS and FY2025 earnings at ($0.31) EPS.
Separately, Stifel Nicolaus reduced their target price on shares of HLS Therapeutics from C$3.75 to C$3.25 in a research note on Tuesday, August 13th.
View Our Latest Stock Analysis on HLS Therapeutics
HLS Therapeutics Stock Performance
TSE HLS traded down C$0.07 during trading hours on Friday, reaching C$3.18. 5,100 shares of the company were exchanged, compared to its average volume of 26,267. The stock has a market capitalization of C$101.09 million, a P/E ratio of -3.15 and a beta of 1.07. The company has a quick ratio of 1.01, a current ratio of 2.02 and a debt-to-equity ratio of 100.44. HLS Therapeutics has a 1 year low of C$3.00 and a 1 year high of C$5.48. The business's 50 day simple moving average is C$3.55 and its 200-day simple moving average is C$3.55.
About HLS Therapeutics
(
Get Free Report)
HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease.
Further Reading
Before you consider HLS Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HLS Therapeutics wasn't on the list.
While HLS Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
